期刊
CELL CHEMICAL BIOLOGY
卷 25, 期 2, 页码 185-+出版社
CELL PRESS
DOI: 10.1016/j.chembiol.2017.11.010
关键词
-
资金
- Stanford Consortium for Innovation, Design, Evaluation and Action (C-IDEA)
- NIH [1K08AI097239, 1DP5OD012119]
- Burroughs Wellcome Fund Career Award for Medical Scientists
- Burroughs Wellcome Fund Investigators in Pathogenesis of Infectious Disease (PATH) Award [1007041]
- Stanford School of Medicine Dean's Postdoctoral Fellowship
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI097239] Funding Source: NIH RePORTER
- OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD012119] Funding Source: NIH RePORTER
The bifunctional farnesyl/geranylgeranyl diphosphate synthase (FPPS/GGPPS) is a key branchpoint enzyme in isoprenoid biosynthesis in Plasmodium falciparum (malaria) parasites. PfFPPS/GGPPS is a validated, high-priority antimalarial drug target. Unfortunately, current bisphosphonate drugs that inhibit FPPS and GGPPS enzymes by acting as a diphosphate substrate analog show poor bioavailability and selectivity for PfFPPS/GGPPS. We identified a new non-bisphosphonate compound, MMV019313, which is highly selective for PfFPPS/GGPPS and showed no activity against human FPPS or GGPPS. Inhibition of PfFPPS/GGPPS by MMV019313, but not bisphosphonates, was disrupted in an S228T variant, demonstrating that MMV019313 and bisphosphonates have distinct modes of inhibition. Molecular docking indicated that MMV019313 did not bind previously characterized substrate sites in PfFPPS/GGPPS. Our finding uncovers a new, selective small-molecule binding site in this important antimalarial drug target with superior druggability compared with the known inhibitor site and sets the stage for the development of Plasmodium-specific FPPS/GGPPS inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据